Drug Trial Radar · NCT04541082
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Actual
Start
Oct 26, 2020
Primary completion
Mar 31, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.
Conditions
- Central Nervous System Neoplasms
- Glioblastoma
- Gliosarcoma, Adult
- Anaplastic Oligodendroglioma
- Anaplastic Astrocytoma
- Pilocytic Astrocytoma
- Oligodendroglioma
- Gliomatosis Cerebri
- Pleomorphic Xanthoastrocytoma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Ependymoma
- Ependymoma, Anaplastic
- Medulloblastoma
- Teratoid Rhabdoid Tumor
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors
- Anaplastic Meningioma
- Atypical Meningioma
- Choroid Plexus Neoplasms
- Pineal Tumor
- Diffuse Astrocytoma
- Glial Tumor
Interventions
ONC206Drug
ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of single-agent, oral ONC206Time frame: 28 Days
- Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)Time frame: 28 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.